As part of our ongoing seminar series, the Centre of Excellence in Severe Asthma hosted Prof. Charles Irvin, for a webinar on “Physiological Phenotyping of Airways Responsiveness in Asthma” on 04 May 2017.
Asthma leads to variable airflow obstruction and airway hyperresponsiveness. The processes that cause these changes are complex. Processes also vary between people. As a result, a one-size-fits all treatment approach is unlikely to be successful.
Prof. Irvin presents findings from a range of clinical trials. Findings highlight differences in response to therapy. In part, differences are explained by patient characteristics. For example, race, body mass and smoking status all effect treatment response.
Lung function assessments also demonstrate differences between people with asthma. In some patients, airway hyperresponsiveness is caused by airway narrowing. However, in other patients reduced lung function results from airway closure.
Differences between patients result from different disease processes. These differences have implications on our understanding of asthma pathogenesis and on treatment strategies.
Prof. Charles Irvin is Director of the Vermont Lung Center and Professor of Medicine; Molecular Physiology & Biophysics at the University of Vermont. His scientific career has focused on understanding the mechanisms of airways dysfunction of the patient with asthma.
Using a multidisciplinary approach including: cell and molecular biology, animal models and systems, transgenic models, physiology, imaging and clinical trial studies, he and his colleagues are attempting to understand the pathophysiological basis of asthma in order to both better diagnose and treat asthma patients.
He has trained 20+ postdoctoral fellows and mentored numerous junior faculty, the vast majority now successfully engaged in research careers.
Prof. Irvin’s travel was supported by AstraZeneca.